Hans Prenen

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Eric Van Cutsem, Josep Tabernero, Radek Lakomý et al. · Journal of Clinical Oncology · 2012 · 1.4K citations

Medicine, Oncology, Pharmacology +15

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko et al. · The Lancet Oncology · 2019 · 537 citations · Full text

Medicine, Oncology, Pharmacology +15

MET is required for the recruitment of anti-tumoural neutrophils

Veronica Finisguerra, Giusy Di Conza, Mario Di Matteo et al. · Nature · 2015 · 506 citations · Full text

Medicine, Immunology, Oncology +12

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · Gastroenterology · 2005 · 494 citations · Full text

Medicine, Oncology, Pharmacology +15